Table 1 Baseline characteristicsa.

From: A randomized placebo-controlled clinical trial for pharmacological activation of BCAA catabolism in patients with type 2 diabetes

 

Mean ± SD

Gender, n (F/M)

3/13

Age, years

66 ± 6

Body weight, kg

90.8 ± 15.4

Height, cm

174.7 ± 8.1

BMI, kg/m2

29.6 ± 3.3

Fasting glucose, mmol/L

8.4 ± 1.5

HbA1c, %

6.5 ± 0.6

ASAT, U/L

23.8 ± 3.9

ALAT, U/L

30.3 ± 7.7

GGT, U/L

32.6 ± 14.6

Potassium (mmol/L)

4.5 ± 0.1

Creatinine (µmol/L)

84.8 ± 4.8

Bilirubin

12.1 ± 2.8

Hemoglobin (mmol/L)

8.8 ± 0.2

Oral glucose lowering medication, n

16

  Metformin only

8

  Sulphonylurea derivates only

2

  Metformin + sulphonylurea derivates

6

  1. an = 16. Screening values are means ± SD BMI body mass index, ASAT aspartate aminotransferase, ALAT alanine aminotransferase, GGT gamma glutamyltransferase.